vs

Side-by-side financial comparison of MYRIAD GENETICS INC (MYGN) and SMITH & WESSON BRANDS, INC. (SWBI). Click either name above to swap in a different company.

MYRIAD GENETICS INC is the larger business by last-quarter revenue ($209.8M vs $124.7M, roughly 1.7× SMITH & WESSON BRANDS, INC.). On growth, MYRIAD GENETICS INC posted the faster year-over-year revenue change (-0.4% vs -3.9%). Over the past eight quarters, MYRIAD GENETICS INC's revenue compounded faster (1.9% CAGR vs -4.8%).

Myriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new products that assess an individual's risk for developing disease later in life, identify a pati...

Smith & Wesson Brands, Inc. (S&W) is an American firearm manufacturer headquartered in Maryville, Tennessee, United States.

MYGN vs SWBI — Head-to-Head

Bigger by revenue
MYGN
MYGN
1.7× larger
MYGN
$209.8M
$124.7M
SWBI
Growing faster (revenue YoY)
MYGN
MYGN
+3.5% gap
MYGN
-0.4%
-3.9%
SWBI
Faster 2-yr revenue CAGR
MYGN
MYGN
Annualised
MYGN
1.9%
-4.8%
SWBI

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
MYGN
MYGN
SWBI
SWBI
Revenue
$209.8M
$124.7M
Net Profit
$1.9M
Gross Margin
70.0%
24.3%
Operating Margin
-2.7%
3.3%
Net Margin
1.5%
Revenue YoY
-0.4%
-3.9%
Net Profit YoY
-53.6%
EPS (diluted)
$-0.09
$0.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MYGN
MYGN
SWBI
SWBI
Q4 25
$209.8M
$124.7M
Q3 25
$205.7M
$85.1M
Q2 25
$213.1M
$140.8M
Q1 25
$195.9M
$115.9M
Q4 24
$210.6M
$129.7M
Q3 24
$213.3M
$88.3M
Q2 24
$211.5M
$159.1M
Q1 24
$202.2M
$137.5M
Net Profit
MYGN
MYGN
SWBI
SWBI
Q4 25
$1.9M
Q3 25
$-27.4M
$-3.4M
Q2 25
$-330.5M
$8.6M
Q1 25
$-100.0K
$2.1M
Q4 24
$4.5M
Q3 24
$-22.1M
$-1.9M
Q2 24
$-36.7M
$27.9M
Q1 24
$-26.0M
$7.9M
Gross Margin
MYGN
MYGN
SWBI
SWBI
Q4 25
70.0%
24.3%
Q3 25
69.9%
25.9%
Q2 25
71.2%
28.8%
Q1 25
68.5%
24.1%
Q4 24
71.7%
26.6%
Q3 24
70.2%
27.4%
Q2 24
69.6%
35.5%
Q1 24
68.1%
28.7%
Operating Margin
MYGN
MYGN
SWBI
SWBI
Q4 25
-2.7%
3.3%
Q3 25
-11.3%
-3.5%
Q2 25
-154.5%
9.3%
Q1 25
-14.8%
4.1%
Q4 24
-18.6%
5.8%
Q3 24
-9.4%
-1.7%
Q2 24
-17.3%
17.4%
Q1 24
-13.8%
8.2%
Net Margin
MYGN
MYGN
SWBI
SWBI
Q4 25
1.5%
Q3 25
-13.3%
-4.0%
Q2 25
-155.1%
6.1%
Q1 25
-0.1%
1.8%
Q4 24
3.5%
Q3 24
-10.4%
-2.1%
Q2 24
-17.4%
17.5%
Q1 24
-12.9%
5.7%
EPS (diluted)
MYGN
MYGN
SWBI
SWBI
Q4 25
$-0.09
$0.04
Q3 25
$-0.29
$-0.08
Q2 25
$-3.57
$0.19
Q1 25
$0.00
$0.05
Q4 24
$-0.47
$0.10
Q3 24
$-0.24
$-0.04
Q2 24
$-0.41
$0.60
Q1 24
$-0.29
$0.17

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MYGN
MYGN
SWBI
SWBI
Cash + ST InvestmentsLiquidity on hand
$149.6M
$22.4M
Total DebtLower is stronger
$119.9M
Stockholders' EquityBook value
$368.0M
$363.2M
Total Assets
$706.6M
$548.6M
Debt / EquityLower = less leverage
0.33×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MYGN
MYGN
SWBI
SWBI
Q4 25
$149.6M
$22.4M
Q3 25
$145.4M
$18.0M
Q2 25
$74.4M
$25.2M
Q1 25
$91.8M
$26.7M
Q4 24
$102.4M
$39.1M
Q3 24
$99.9M
$35.5M
Q2 24
$97.3M
$60.8M
Q1 24
$104.3M
$47.4M
Total Debt
MYGN
MYGN
SWBI
SWBI
Q4 25
$119.9M
Q3 25
$119.5M
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
MYGN
MYGN
SWBI
SWBI
Q4 25
$368.0M
$363.2M
Q3 25
$372.8M
$364.4M
Q2 25
$388.1M
$372.5M
Q1 25
$704.9M
$366.9M
Q4 24
$701.1M
$371.5M
Q3 24
$731.7M
$380.0M
Q2 24
$740.5M
$399.9M
Q1 24
$760.0M
$376.4M
Total Assets
MYGN
MYGN
SWBI
SWBI
Q4 25
$706.6M
$548.6M
Q3 25
$728.1M
$554.6M
Q2 25
$677.3M
$559.6M
Q1 25
$1.0B
$578.9M
Q4 24
$1.0B
$587.4M
Q3 24
$1.1B
$571.3M
Q2 24
$1.1B
$577.4M
Q1 24
$1.1B
$570.6M
Debt / Equity
MYGN
MYGN
SWBI
SWBI
Q4 25
0.33×
Q3 25
0.32×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MYGN
MYGN
SWBI
SWBI
Operating Cash FlowLast quarter
$10.6M
$27.3M
Free Cash FlowOCF − Capex
$16.3M
FCF MarginFCF / Revenue
13.1%
Capex IntensityCapex / Revenue
8.8%
Cash ConversionOCF / Net Profit
14.22×
TTM Free Cash FlowTrailing 4 quarters
$21.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MYGN
MYGN
SWBI
SWBI
Q4 25
$10.6M
$27.3M
Q3 25
$21.1M
$-8.1M
Q2 25
$-13.6M
$40.8M
Q1 25
$-16.3M
$-9.8M
Q4 24
$6.6M
$-7.4M
Q3 24
$700.0K
$-30.8M
Q2 24
$2.6M
$43.7M
Q1 24
$-18.6M
$25.2M
Free Cash Flow
MYGN
MYGN
SWBI
SWBI
Q4 25
$16.3M
Q3 25
$-12.4M
Q2 25
$33.5M
Q1 25
$-16.1M
Q4 24
$-10.7M
Q3 24
$-35.5M
Q2 24
$38.2M
Q1 24
$7.0M
FCF Margin
MYGN
MYGN
SWBI
SWBI
Q4 25
13.1%
Q3 25
-14.6%
Q2 25
23.8%
Q1 25
-13.9%
Q4 24
-8.3%
Q3 24
-40.2%
Q2 24
24.0%
Q1 24
5.1%
Capex Intensity
MYGN
MYGN
SWBI
SWBI
Q4 25
8.8%
Q3 25
5.0%
Q2 25
5.2%
Q1 25
5.4%
Q4 24
2.5%
Q3 24
5.3%
Q2 24
3.5%
Q1 24
13.2%
Cash Conversion
MYGN
MYGN
SWBI
SWBI
Q4 25
14.22×
Q3 25
Q2 25
4.73×
Q1 25
-4.68×
Q4 24
-1.63×
Q3 24
Q2 24
1.57×
Q1 24
3.20×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons